Additionally, all subjects in the 600 mg twice daily regimen group achieved HCV RNA to below LLOQ ( 20 percent in one or more treatment arms) in patients receiving MK-7009 versus patients receiving placebo, respectively, were nausea (28 to 40 percent versus 26 percent), headache (16 to 45 percent versus 37 percent), fatigue (5 to 35 percent versus 32 percent), flu-like symptoms (20 to 26 percent versus 16 percent), anorexia (5 to 25 percent versus 11 percent), diarrhea (6 to 25 percent versus 2